We’re Doubling Down on Fighting Cancer

Treating cancer effectively requires the best access to doctors and specialists, the best medicine, and a personalized approach that treats the whole patient.

Clinical trials play an essential role in the fight against cancer. They help to scientifically validate that a new treatment works better than the current standard of care.

Advanced Cancer Treatments

Catholic Health and NewYork-Presbyterian have joined forces to advance the future of cancer care and push the boundaries of cancer treatment.

Patients at the Catholic Health Cancer Institute have direct access to state-of-the-art clinical trials and investigational drug programs at Columbia University Herbert Irving Comprehensive Cancer Center, an NCI-designated center recognized for its approach to prevention, diagnosis and treatment. All trials and treatments are administered at Catholic Health Cancer Institute locations across Long Island.

Together, Catholic Health and NewYork-Presbyterian are broadening access to innovative clinical trials that generate real-world evidence and translate breakthroughs faster— so that more patients benefit from the most effective, personalized care and an improved quality of life.

Speak with your Catholic Health oncologist or complete the form below to decide if a clinical trial is right for you.

Current Open Clinical Trials

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study 

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Integration of Immunotherapy into adjuvant therapy for resected NCLC: ALCHEMIST CHEMO-IO (ACCIO)

Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study 

St. Francis Hospital Cardio-Oncology Registry 

  • Principal Investigator: Dr. Haoyi Zheng

Request More Information About Clinical Trials

Preferred Method of Contact

Clinical Excellence. Compassionate Care.

Cancer Services

Diagnosis and treatment for all types and stages of cancer.

Catholic Health Cancer Care Team

Board-certified oncologists and a supporting team of cancer specialists.

Catholic Health Cancer Institutes

Comprehensive cancer services at locations across Long Island.